9.8% Average Loss With Semaglutide in HFpEF and Type 2 Diabetes
STEP-HFpEF DM studied once-weekly semaglutide in adults who had obesity-related heart failure with preserved ejection fraction and type 2 diabetes. It found improvements in weight and a patient-reported heart-failure health-status score under a one-year trial protocol. The study is not a substitute for heart-failure or diabetes care and does not establish an HFpEF indication.
At week 52, mean body-weight change was −9.8% with semaglutide and −3.4% with placebo; KCCQ clinical summary score change was +13.7 and +6.4 points, respectively.
The estimated between-group difference was −6.4 percentage points for weight and +7.3 points for KCCQ clinical summary score. Six-minute walk distance improved 14.3 meters more with semaglutide. Serious adverse events occurred in 17.7% of semaglutide participants and 28.8% of placebo participants; adverse-event discontinuation occurred in 10.6% and 8.2%, respectively.
Turn the study result into a better program comparison
If this result prompts you to explore GLP-1 care, use it to ask better questions rather than to select a program. Compare providers on available plans, clinician access, medication status, follow-up, public price terms, and enrollment conditions. These reviewed brands have category-matched GLP-1 offers; none participated in or is endorsed by this study.
From $49 – $129/mo · Editorial score 4.7/5
Featured value terms: semaglutide $49/mo or tirzepatide $89/mo with 12-month prepayment; $99/$129 month to month.
We may earn a commission through provider links. Matching affiliate offers and editorial priorities affect inclusion and suggested order in commercial guides. Scores are not clinical endorsements. Disclosure · Methodology
Study details
- Population
- 616 adults with obesity-related HFpEF, a left-ventricular ejection fraction of at least 45%, and type 2 diabetes
- Follow-up
- 52-week treatment period; 57 weeks for the hierarchical composite follow-up
- Treatment comparison
- Once-weekly subcutaneous semaglutide escalated to 2.4 mg compared with placebo, added to background diabetes treatment
- Study design
- Multicountry, double-blind, randomized, placebo-controlled trial
A study result is not a personal treatment plan
The study does not determine whether semaglutide is appropriate for an individual with heart failure or type 2 diabetes. It did not compare online providers, insurance coverage, pharmacies, affordability, or diabetes-care plans. People with heart failure or diabetes should review treatment decisions with their own licensed clinician and care team.
Compare semaglutide and tirzepatide programsWhat this result does not show
- The trial was not designed or powered to establish effects on heart-failure hospitalizations or urgent heart-failure visits; its event count was small.
- The 52-week follow-up does not establish longer-term durability of the symptom, function, weight, or safety results.
- The population had obesity-related HFpEF and type 2 diabetes with specific entry criteria, so results do not directly generalize to people without those conditions.
- The study does not compare telehealth providers, affordability, insurance coverage, pharmacy access, or individual treatment outcomes.
- The study was funded by Novo Nordisk; the peer-reviewed paper and disclosure materials are linked at the end of this article.
Related Studies
Explore other peer-reviewed results in Evidence Watch before comparing programs or discussing options with a clinician.
Primary peer-reviewed source
Read the full paper, methodology, conflict-of-interest disclosures, and supplementary materials before drawing conclusions beyond this plain-English summary.
Read the study at New England Journal of Medicine